Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening

HIV Clinical Trials

Volumn 15, Issue 2, 2014, Pages 62-68

  Piwowar Manning, Estelle ^a   Fogel, Jessica ^a   Laeyendecker, Oliver ^a,b   Wolf, Shauna ^a   Cummings, Vanessa ^a   Marzinke, Mark ^a   Clarke, William ^a   Breaud, Autumn ^a   Wendel, Sarah ^b   Wang, Lei ^c   Swanson, Priscilla ^d   Hackett Jr, John ^d   Mannheimer, Sharon ^e   Del Rio, Carlos ^f   Kuo, Irene ^g   Harawa, Nina ^h   Koblin, Beryl ⁱ   Moore, Richard ^a   Blankson, Joel ^a   Eshleman, Susan ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ABBOTT LABORATORIES   (United States)

^e Department of Medicine   (United States)

^f EMORY UNIVERSITY   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

ⁱ NEW YORK BLOOD CENTER   (United States)

Author keywords

antiretroviral therapy; elite controller; HIV; rapid test; viral suppression

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ANALYZER; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIAGNOSTIC ERROR; DRUG DETERMINATION; EVALUATION STUDY; FEMALE; FOLLOW UP; HIV RAPID TEST; HIV SCREENING TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; IMMUNOASSAY ANALYZER; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING TEST; VIRUS LOAD; WESTERN BLOTTING; WESTERN BLOTTING ANALYZER;

ANTIRETROVIRAL THERAPY; ELITE CONTROLLER; HIV; RAPID TEST; VIRAL SUPPRESSION;

ADULT; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; BLOTTING, WESTERN; COHORT STUDIES; FALSE NEGATIVE REACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOASSAY; MALE; MASS SCREENING; MIDDLE AGED; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84898021762     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1502-62     Document Type: Article

References (21)

1. Patel P, Bennett B, Sullivan T, Parker MM, Heffelfi nger JD, Sullivan PS. Rapid HIV screening: Missed opportunities for HIV diagnosis and prevention. J Clin Virol. 2012;54(1): 42-47.
2. Louie B, Wong E, Klausner JD, et al. Assessment of rapid tests for detection of human immunodeficiency virusspecifi c antibodies in recently infected individuals. J Clin Microbiol. 2008;46(4):1494-1497. (Pubitemid 351563599)
3. Brown P, Merline JR, Levine D, Minces LR. Repeatedly false-negative rapid HIV test results in a patient with undiagnosed advanced AIDS. Ann Intern Med. 2008;149(1): 71-72. (Pubitemid 351931151)
4. O'Connell RJ, Merritt TM, Malia JA, et al. Performance of the OraQuick rapid antibody test for diagnosis of human immunodefi ciency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol. 2003;41(5):2153-2155. (Pubitemid 36576551)
5. Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis. 2011;52(2):257-263.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587- 2599.
7. Sullivan AK, Savage EJ, Lowndes CM, et al. Non-disclosure of HIV status in UK sexual health clinics-a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey. Sex Transm Infect. 2013;89(2):120-121.
8. Marzinke MA, Clarke W, Wang L, et al. Non-disclosure of HIV status in a clinical trial setting: Antiretroviral drug screening can help distinguish between newly-diagnosed and previously-diagnosed HIV infection. Clin Infect Dis. 2014;58(1):117-120.
9. Fogel JM, Wang L, Parsons TL, et al. Undisclosed antiretroviral drug use in a multi-national clinical trial (HPTN 052). J Infect Dis. 2013;208(10):1624-1628.
10. Koblin BA, Mayer KH, Eshleman SH, et al. Correlates of HIV acquisition in a cohort of black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. PLoS One. 2013;8(7):e70413.
11. Mayer KH, Wang L, Koblin B, et al. Concomitant socioeconomic, behavioral, and biological factors associated with the disproportionate HIV infection burden among black men who have sex with men in 6 U.S. cities. PLoS One. 2014;9(1):e87298
12. Han Y, Lai J, Barditch-Crovo P, et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS. 2008;22(4):541-544. (Pubitemid 351317300)
13. Wendel SK, Mullis CE, Eshleman SH, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One. 2013;8(2):e55525.
14. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defi c Syndr Hum Retrovirol. 1998;17(Suppl 1):S38-41. (Pubitemid 128708058)
15. Centers for Disease Control and Prevention. HIV/AIDS Prevention. Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform. http://www.cdc.gov/hiv/pdf/ testing-AdvantagesDisadvantages.pdf. Accessed January 23, 2014.
16. Marzinke MA, Breaud A, Parsons TL, et al. The development and validation of a full scan-high resolution accurate mass spectrometric (HRMS) screening method for the qualitative monitoring of antiretroviral agents in human blood. Manuscript submitted for publication.
17. Laeyendecker O, Brookmeyer R, Cousins MM, et al. HIV incidence determination in the United States: A multiassay approach. J Infect Dis. 2013;207(2):232-239.
18. Centers for Disease Control and Prevention. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm-United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2013;62(24):489-494.
19. US Food and Drug Administration. INSTI HIV-1 Antibody Test Kit [package insert]. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ Approved-Products/PremarketApprovalsPMAs/UCM235249.pdf. Accessed January 18, 2013.
20. US Food and Drug Administration. OraQuick Advance Rapid HIV-1/2 Antibody Test [package insert]. http://www. fda.gov/downloads/BiologicsBloodVaccines/ BloodBlood-Products/ApprovedProducts/PremarketApprovalsPMAs/ucm091917.pdf. Accessed January 18, 2013.
21. Brennan CA, Yamaguchi J, Vallari A, Swanson P, Hackett J Jr. ARCHITECT HIV Ag/Ab Combo assay: Correlation of HIV-1 p24 antigen sensitivity and RNA viral load using genetically diverse virus isolates. J Clin Virol. 2013;57(2):169-172.